Alnylam Pharmaceuticals has been generating significant attention due to various activities that include strategic partnerships, financial performances, and changes in shareholding. The company has sunk its roots deeper into the biotech industry by comprehensively collaborating with Viz.ai and Tenaya, aiming to improve the plight of cardiac amyloidosis patients and discover new gene targets for cardiovascular drugs. These partnerships will enhance
Alnylam's innovations in the biotechnology market, providing it with fresh insights and broader access to resources.
Alnylam is likewise turning heads in finance with the company's prediction of $5.3 billion revenue by 2026. It also plans to invest $250 million to broaden its manufacturing facilities. Amid this, there's been fluctuation in
Alnylam's shares as different asset management firms revise their holdings. Both Assenagon and Hudson Bay Capital decreased their positions, while others like SG Americas Securities, Wealth Enhancement, and Integral Health Asset increased theirs. Still, Alnylam's balance sheet remains healthy and analysts maintain a 'buy' rating for their stock. Despite facing challenges in the TTR space, the company has remained undeterred and continues to expand its portfolio.
Alnylam Pharmaceuticals News Analytics from Thu, 18 Sep 2025 07:00:00 GMT to Sat, 28 Mar 2026 08:36:01 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor 1
